Seres Ther­a­peu­tics sheds about 160 jobs to fo­cus on com­mer­cial C. diff pill

Seres Ther­a­peu­tics will end most R&D work to fo­cus re­sources on its com­mer­cial prod­uct in a move that will re­sult in let­ting go about 160 work­ers, or 41% of the staff, the biotech said Thurs­day morn­ing.

The Boston biotech said it will place pri­or­i­ty on its pill Vow­st, which se­cured FDA ap­proval in April for pa­tients re­cov­er­ing from re­peat­ing in­fec­tions of Clostrid­ioides dif­fi­cile, com­mon­ly called C. diff.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER